MSK Study Finds New Insights, Jan 20th, 2023

Memorial Sloan Kettering Cancer Center

New research from Memorial Sloan Kettering Cancer Center (MSK) and the Sloan Kettering Institute — MSK’s experimental research arm — explores novel predictors of immunotherapy effectiveness against lung cancer; identifies how a high-fat diet hinders intestinal damage repair; reports findings from a clinical trial for people with androgen receptor-positive salivary gland cancer; and aims to understand the impact of tumor mutational burden on patients with locally advanced non-small cell lung cancer.

Study suggests novel predictors of immunotherapy effectiveness against lung cancer

Immune checkpoint inhibitors have been a remarkable advance for the treatment of lung cancer. But most patients’ cancers either don’t respond to the treatment or the response is short-lived. A new study led by MSK medical oncologist Andrew Chow, MD, PhD, a member of the lab of co-senior author Charles Rudin, MD, PhD

/Public Release. This material from the originating organization/author(s) may be of a point-in-time nature, edited for clarity, style and length. The views and opinions expressed are those of the author(s).View in full here.